Выбор лечебной тактики при тромбоэмболии легочной артерии средневысокого риска и хронической болезни почек
Аннотация
Представлен клинический разбор пожилого больного с тромбоэмболией легочной артерии средневысокого риска и хронической болезнью почек. Даны рекомендации по современным принципам диагностики, выбора лечебной тактики у больных с данной патологией. Большое внимание уделено вопросам безопасности антикоагулянтного лечения.
Об авторе
А. Л. Комаров
«Институт клинической кардиологии им. А. Л. Мясникова» ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России.
Россия
Москва.
Россия
Москва.
Список литературы
1. Cohen A.T., Agnelli G., Anderson F.A. et al.; VTE Impact Assessment Group in Europe (VITAE). The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756–764.
2. Heit J.A., Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005 Aug;3(8):1611-7.
3. Levey A.S., Stevens L.A., Schmid C.H. et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612.
4. Monreal M., Falgá C., Valle R. et al.; RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006;119(12):1073–1079. DOI: 10.1016/j.amjmed.2006.04.028.
5. Böttger B., Wehling M., Bauersachs R.M. et al. Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: a retrospective analysis based on 6,725 VTE patients. Thromb Res 2014;134(5):1014–1019. DOI: 10.1016/j.thromres.2014.09.003.
6. Bauersachs R.M., Lensing A.W., Prins M.H. et al.. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J 2014;12:25. DOI: 10.1186/1477-9560-12-25.
7. Steffel J., Verhamme P., Potpara T.S. et al., ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39(16):1330–1393. DOI: 10.1093/eurheartj/ehy136.
8. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014 Nov 14; 35(43):3033-69. DOI: 10.1093/eurheartj/ehu283.
9. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. Chest 2016;149(2):315–352.
10. Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. A Scientific Statement From the American Heart Association. Circulation 2011;123:1788–1830.
11. Engelberger R.P., Kucher N. Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. Eur Heart J 2014;35(12):758–764. DOI: 10.1093/eurheartj/ehu029.
12. Stein P.D., Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 2012;125(5):465–470. DOI: 10.1016/j.amjmed.2011.10.015.
13. Jiménez D., de Miguel-Díez J., Guijarro R. et al.; RIETE Investigators. Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. J Am Coll Cardiol 2016;67(2):162–170. DOI: 10.1016/j.jacc.2015.10.060.
14. Kline J.A., Steuerwald M.T., Marchick M.R. et al. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009;136(5):1202–1210. DOI: 10.1378/chest.08-2988.
15. Meyer G., Vicaut E., Danays T. et al. for PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014;370(15):1402–1411. DOI: 10.1056/NEJMoa1302097.
16. Konstantinides S.V., Vicaut E., Danays T. et al. Impact of Thrombo lytic Therapy on the Long-Term Outcome of Inter mediate-Risk Pulmonary Embolism. J Am Coll Cardiol 2017;69(12):1536–1544. DOI: 10.1016/j.jacc.2016.12.039.
17. Chatterjee S., Chakraborty A., Weinberg I. et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014;311(23):2414–2421. DOI: 10.1001/jama.2014.5990.
18. Geldhof V., Vandenbriele C., Verhamme P., Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 2014;12:21. DOI: 10.1186/1477-9560-12-21.
19. Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hebert R, Hogan DB. A brief clinical instrument to classify frailty in elderly people. Lancet 1999;353:205–206.
20. Tkacheva O.N., Runikhina N.K., Vorobiova N.M. et al. Antithrom bo tic therapy in elderly and senile age: an expert consensus. Cardiovascular Therapy and Prevention. 2017;16(3):4-33. https://doi.org/10.15829/1728-8800-2017-3-4-33 Russian (Ткачева О.Н., Рунихина Н.К., Воробьева Н.М. и др. Антитромбо тическая терапия в пожилом и старческом возрасте: согласованное мне-ние экспертов. Кардиоваскулярная терапия и профилактика 2017;16(3):4–33.)
21. Wang Y., Wang C., Chen Z. et al.; Chinese EINSTEIN Investigators. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thromb J 2013;11(1):25. DOI: 10.1186/1477-9560-11-25.
22. Moustafa F., Giorgi Pierfranceschi M., Di Micco P. et al.; RIETE Investigators. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. Res Pract Thromb Haemost 2017;1(2):172–179. DOI: 10.1002/rth2.12036.
23. Prins M.H., Lensing A.W., Bauersachs R. et al.; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11(1):21. DOI: 10.1186/1477-9560-11-21.
24. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. The EINSTEIN-PE Investigators. N Engl J Med 2012;366:1287–1297.
25. Böhm M., Ezekowitz M.D., Connolly S.J. et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol 2015;65(23):2481–2493. DOI: 10.1016/j.jacc.2015.03.577.
26. Fordyce C.B., Hellkamp A.S., Lokhnygina Y. et al.; ROCKET AF Steering Committee and Investigators. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016;134(1):37–47. DOI: 10.1161/CIRCULATIONAHA.116.021890.
27. Rossijskie klinicheskie rekomendacii po diagnostike, lecheniju i profilaktike venoznyh trombojembolicheskih oslozhnenij. Flebologija 2015;4(2):1–52. Russian (Российские клинические рекоменда-ции по диагностике, лечению и профилактике венозных тром-боэмболических осложнений. Флебология 2015;4(2):1-52.)
28. Prins M.H., Lensing A.W.A., Prandoni P. et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv 2018;2(7):788–796. DOI: 10.1182/bloodadvances.2018017160.
29. Brighton T.A., Eikelboom J.W., Mann K. et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367:1979–1987.
30. Becattini C., Agnelli G., Schenone A. et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959–1967.
31. Weitz JI, Lensing AWA, Prins MH, et al for EINSTEIN CHOICE Investigators. N Engl J Med 2017 Mar 30;376(13):1211–1222. DOI: 10.1056/NEJMoa1700518.
32. Palareti G., Cosmi B., Legnani C. et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355(17):1780–1789.
33. Palareti G., Cosmi B., Legnani C. et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 2014;124(2):196–203.
Для цитирования:
Комаров А.Л. Выбор лечебной тактики при тромбоэмболии легочной артерии средневысокого риска и хронической болезни почек. Кардиология. 2019;59(2):88-96. https://doi.org/10.18087/cardio.2019.2.10232
For citation:
Komarov A.L. The Choice of Treatment Tactics for Thromboembolism of the Pulmonary Artery of Medium-High Risk and Chronic Kidney Disease. Kardiologiia. 2019;59(2):88-96. (In Russ.) https://doi.org/10.18087/cardio.2019.2.10232
Просмотров: 1216
Послать статью по эл. почте 
Оставить комментарий 